We need to be above $2.00 to up list to NASDAQ. We wouldn't want to be too close to $2.00 in case we fall backwards and then get de-listed. So I would think we'd RS all the way up to $4.00 at least. At .07 cents now we'd need an almost 1:60 Reverse Split.
Gerald won't up list in weakness. We need to get up to .20 cents and have revenues coming in to keep us from falling back after we RS and up list.
I think we'll up list in October or thereabouts when the diagnostic division starts bringing in revenue.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links